Payment overview · 2025
General Payments
$569.54
30 reported records · 13 companies
Healthcare provider profile · identity verified
John C Collins, DO
Allopathic & Osteopathic Physicians|Family Medicine · KIRKSVILLE, MO · NPI 1689659559
Verified facts
What the public records show
CMS Open Payments records show John C Collins, DO received $569.54 in general payments during 2025 across 30 reported records.
AstraZeneca Pharmaceuticals LP accounted for 31.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rexulti, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $177.38 | 31.1% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $160.27 | 28.1% | 11 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $37.91 | 6.7% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $37.09 | 6.5% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $29.10 | 5.1% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.27 | 5.0% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $19.55 | 3.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.40 | 3.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.71 | 2.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.24 | 2.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.06 | 2.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $9.79 | 1.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $9.77 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $569.54 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $160.27 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $141.24 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.05 | 9 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $37.91 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $37.09 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $36.14 | 2 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $29.10 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $28.27 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $9.79 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $9.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 374 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 311 | 57 |
| Omeprazole | Omeprazole | 188 | 35 |
| Lisinopril | Lisinopril | 158 | 35 |
| Tramadol Hcl | Tramadol Hcl | 156 | 38 |
| Losartan Potassium | Losartan Potassium | 117 | 22 |
| Metformin Hcl | Metformin Hcl | 115 | 21 |
| Carvedilol | Carvedilol | 113 | 20 |
| Potassium Chloride | Potassium Chloride | 112 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 110 | 29 |
| Amlodipine Besylate | Amlodipine Besylate | 109 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 101 | 12 |
| Gabapentin | Gabapentin | 95 | 20 |
| Buspirone Hcl | Buspirone Hcl | 92 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 83 | 15 |
| Alprazolam | Alprazolam | 73 | 18 |
| Simvastatin | Simvastatin | 72 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 70 | 18 |
| Furosemide | Furosemide | 68 | 17 |
| Clonazepam | Clonazepam | 66 | 16 |
| Memantine Hcl | Memantine Hcl | 66 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 12 |
| Celecoxib | Celecoxib | 55 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 55 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 51 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 24 |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Vascepa | Icosapent Ethyl | 48 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 47 | suppressed |
| Fentanyl | Fentanyl | 47 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 13 |
| Famotidine | Famotidine | 46 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 46 | suppressed |
| Rybelsus | Semaglutide | 46 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 45 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 44 | suppressed |
| Eliquis | Apixaban | 44 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 44 | 11 |
| Montelukast Sodium | Montelukast Sodium | 43 | 11 |
| Ozempic | Semaglutide | 43 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 40 | suppressed |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 39 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 36 | suppressed |
| Jardiance | Empagliflozin | 36 | suppressed |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Prednisone | Prednisone | 35 | 27 |
| Atenolol | Atenolol | 34 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 34 | suppressed |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Meloxicam | Meloxicam | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | suppressed |
| Allopurinol | Allopurinol | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 22 |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Cefdinir | Cefdinir | 24 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 24 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 21 | 13 |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 18 | suppressed |
| Lubiprostone | Lubiprostone | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Np Thyroid | Thyroid,pork | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Naproxen | Naproxen | 17 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 15 |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $569.54 · 30 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, LEQVIO, M-M-R II, Ozempic, Prolastin-C Liquid, Quviviq, REXULTI, Rybelsus, VAXNEUVANCE, VOQUEZNA, VRAYLAR, ZENPEP | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error